fashion -WSS

fashion

author：leisure time 2025-10-01 02:15:35 - browse：561

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Paxlovid study fails to answer questions over benefit for broader groups

focus

WSS

Lung cancer screening guidelines updated for cigarette smokers

Bill would allow buprenorphine prescription for addiction via telehealth

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Key Senate panel to consider PBM, drug pricing reform package

The strategy behind pharma's lawsuits over drug pricing reform

Brain injuries and the importance of a second opinion

entertainment

fashion

knowledge

Walensky prepares to leave CDC — and Congress — behind

The battle over the Brookhaven Landfill on Long Island

As demand for Covid shots wanes, Moderna seeks its next success

Brain injuries and the importance of a second opinion

DIEP, the 'gold standard' of breast reconstruction, is under threat

All of Us, NIH's precision medicine initiative, gets a big boost

Medicare details structure of new drug price negotiation program

WATCH: Why do fingernails fall off when they're damaged?

Psychedelics group wrestles with new pharma identity

Medicare proceeds with plan to claw back hospital funds

leisure time

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Death of patient in Alzheimer’s trial raises question of possible risks

Explaining an after

entertainment

leisure time

focus

entertainment